Public & philanthropic financial contribution to the development of new drugs 2: EC-FP7 Health Projects
Duration: July 2020 – January 2021
Following on from the previous project on public funding for research and development (R&D) of products (1), the analysis now focuses on EU research funding for the development of pharmaceuticals.
All FP7 projects (2007-2013) on late-stage clinical research are analysed and case studies are used to shed light on public contributions to the development of concrete products, but also on publicly invested risk capital.
Schmidt L, Sehic O, Wild C (2021) EU FP7 research funding for an orphan drug (Orfadin®) and vaccine (Hep C) development: a success and a failure, submitted.
(1) Schmidt L, Wild C (2020) Assessing the public and philanthropic financial contribution to the development of new drugs: a bibliographic analysis. Science, Technology & Public Policy (STPP), 4 (1): 8-14.